Tuberculosis is a leading cause of mortality and morbidity worldwide. Diagnosis, treatment, and prevention of TB has become more complex because of resistance to commonly used antituberculous drugs.
Drug resistant pulmonary tuberculosis refers to tuberculosis caused by an isolate of Mycobacterium tuberculosis that is resistant to one or more antituberculousis drugs. The drug resistant pulmonary tuberculosis market is expected to experience substantial growth during the forecast period due to rising incidence of the disease.
The market is segmented based on types, therapy types and distribution channel. Based on types, the market is segmented into mono drug resistant tuberculosis, multidrug resistant tuberculosis, extensive drug resistant tuberculosis and totally drug resistant tuberculosis.
Multidrug resistant tuberculosis is predicted to be the highest contributor in this segment due to its growing incidence.With the COVID-19 breakout in December 2019, the disease has affected more than 200 countries.
To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-12552
Therefore, it is important to take this into consideration while addressing drug resistant pulmonary tuberculosis market. The disease may have led to temporary lag in the drug resistant pulmonary tuberculosis market, but in the long run the market is expected to pace up and flourish at a significant rate during the forecast period 2020-2030.
Drug Resistant Pulmonary Tuberculosis Market: Drivers and Restraints
The rising prevalence of multidrug resistant tuberculosis is expected to be the major factor to drive the growth of drug resistant pulmonary tuberculosis market. Increasing research and development in novel drug development is also expected to boost the global drug resistant pulmonary tuberculosis market.
Additionally, collaborations among international organizations, such as UNICEF, WHO, and TB alliance, focusing on development of treatment with shorter regimensin order to fight drug resistance is expected to address unmet medical needs, which will lead to significant market growth during the forecast period.
However, some adverse drug reaction to the body may restrict the growth of drug resistant pulmonary tuberculosis market.
Drug Resistant Pulmonary Tuberculosis Market: Overview
Drug resistant pulmonary tuberculosis market is expected to experience steady growth during the forecast period due to increasing prevalence of the disease.
Based on disease type, the market is segmented into totally drug resistant tuberculosis, extensive drug resistant tuberculosis, multidrug resistant tuberculosis and mono drug resistant tuberculosis. The multidrug resistant tuberculosis is expected to grow substantially in this segment due to rising incidence of multidrug tuberculosis.
Based on therapy type, the global drug resistant pulmonary tuberculosis market is segmented into first line anti TB- drugs and second line anti TB-drugs. In this segment, the second line is expected to contribute major revenue as first line anti TB-drugs can be used only to treat mono drug resistant tuberculosis.
The first line anti TB- drugs is further segmented into isoniazid, ethambutol, pyrazinamide, rifambutin, streptomycin and others. Furthermore, the second line anti TB-drugs market is segmented into cycloserine, moxifloxacin, gatifloxacin, Amikacin, Ethionomide, capreomycin and others.
Based of distribution channel, the drug resistant pulmonary tuberculosis is segmented into hospital pharmacy, retail pharmacy and online pharmacy. Retail pharmacy is expected to dominate the market during the forecast period.
Drug Resistant Pulmonary Tuberculosis Market: Key players
Some of the players identified in the drug resistant pulmonary tuberculosis marketinclude:
- Bayer AG
- Lupin Ltd.
- Sandoz International GmbH
- GlaxoSmithKline
- Zydus Cadila
- Pfizer Inc.
- Sanofi
For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-12552
Why Future Market Insights?
• Comprehensive analysis on evolving purchase pattern across different geographies
• Detailed insights of market segments and sub-segments for historical as well as forecast period
• A competitive analysis of prominent players and emerging players in the keyword market
• Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years
Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario
About FMI:
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Contact Us:
Mr. Debashish Roy
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com